Epitalon
A synthetic tetrapeptide associated with aging research, supported mainly by limited and difficult-to-verify clinical literature.
On this page
WHAT THE EVIDENCE SAYS
Epitalon evidence summary.
Epitalon's longevity narrative is much stronger than its verifiable modern human evidence. The record remains hypothesis-generating, not outcome-proving.
01 / CLASSIFICATION
What is Epitalon?
Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.
02 / EVIDENCE
Epitalon human and preclinical evidence.
The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.
03 / STATUS
Epitalon FDA and sport status.
Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.
04 / RESEARCH AREAS
What is Epitalon being studied for?
05 / COMPARISONS
Compare Epitalon.
06 / LATEST & DEFINING SOURCES
Epitalon primary and official sources.
07 / QUESTIONS
Questions about Epitalon.
Start with identity, research, human evidence, approval, sport status, and the limits of the current record.
Epitalon's longevity narrative is much stronger than its verifiable modern human evidence. The record remains hypothesis-generating, not outcome-proving.
Current source-backed research areas include Aging biology, Oxidative stress, Gene expression, Pineal peptide research. These areas describe investigation, not established personal benefit.
Current U.S. status for Epitalon: No FDA-approved Epitalon drug product; FDA enforcement records have described Epitalon products as unapproved new drugs.
Current sport-status snapshot for Epitalon: Not specifically named in the 2026 WADA List; athletes should verify current status and product contents.
Older, geographically concentrated, or difficult-to-verify reports should not be upgraded into a general anti-aging claim.